Mineralys' lorundrostat lowers systolic blood pressure by 17.8 mmHg at 48 weeks in extension trial
MLYS•Mineralys Therapeutics said lorundrostat lowered systolic blood pressure by 17.8 mmHg at 48 weeks in the Transform-HTN extension trial. More than half of participants reached the recommended systolic blood pressure target, and the FDA is reviewing the drug as an add-on hypertension treatment, with a decision target date of December 22, 2026.
1. Extension trial results
Mineralys Therapeutics presented Transform-HTN results on November 8, 2026, showing sustained blood pressure reductions with lorundrostat in people with uncontrolled or resistant hypertension. Reductions persisted for nearly a year, and more than half of participants reached the recommended systolic blood pressure target. Long-term treatment was well tolerated, with no new clinically relevant safety findings compared with Launch-HTN. FDA review of lorundrostat as an add-on hypertension treatment is underway, with a decision target date of December 22, 2026.
